“It is likely that the remediation by Celltrion of the issues addressed in the warning letter will result in a delayed approval of the biosimilar products by the FDA,” Teva told investors.
In Teva’s 2017 full-year and fourth-quarter financial results report, the company acknowledged that it is facing a substantial setback after its Republic of Korea-based partner, Celltrion, received a warning letter from the FDA that raised issues related to manufacturing.
“Celltrion is our sole source for [active pharmaceutical ingredient, API] production for fremanezumab and also for Celltrion’s products CT-P10 [biosimilar rituximab] and CT-P6 [biosimilar trastuzumab],” said Teva in its earnings report, adding that “It is likely that the remediation by Celltrion of the issues addressed in the warning letter will result in a delayed approval of the biosimilar products by the FDA.” Teva assured investors that “We are in active dialogue with the FDA in an effort to maintain our priority date for the approval of fremanezumab.”
Fremanezumab is Teva’s monoclonal antibody for the preventive treatment of migraine. The company submitted a Biologics License Application for the product to the FDA in December 2017. Teva had hopes of launching the innovative biologic in 2018.
However, Fierce Pharma reports that Teva’s CEO, Kare Schultz, said that “It could take 6 to 18 months to resolve a warning letter, but we are having [the active pharmaceutical ingredient] API made there and that is not affected by the warning letter, so an approval could be sooner, but we don’t know.” Shultz added that the warning letter addressed problems associated with the finished products portion of the plant, and not the production area.
The letter, recently released in full by the FDA, cites Celltrion’s failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes. It also says that Celltrion failed to thoroughly investigate any unexplained discrepancy in its products’ vials, or to investigate visible particles in finished drug products.
The news comes at an already tumultuous time for Israel-based Teva and for Shultz, who is leading the company through a 2-year streamlining process that includes laying off 25% of Teva's workforce and closing manufacturing and research and development sites worldwide.
Teva's stock dropped by 10.6% on Thursday, and by another 4.5% Friday morning.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.